{"id":"ranibizumab-injection-and-ttt-icg-based","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Retinal pigment epithelium changes"},{"rate":null,"effect":"Endophthalmitis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab inhibits VEGF-A, a key driver of pathological neovascularization in retinal diseases. The combination with ICG-guided TTT allows real-time visualization of choroidal vasculature during thermal treatment, enabling precise ablation of abnormal vessels while minimizing damage to surrounding healthy tissue. This dual approach targets both the angiogenic stimulus and the structural abnormalities in retinal vascular disease.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:13.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Diabetic macular edema (DME)"}]},"trialDetails":[{"nctId":"NCT00680225","phase":"PHASE3","title":"Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma","status":"COMPLETED","sponsor":"New England Retina Associates","startDate":"2007-09","conditions":"Choroidal Melanoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucentis injection"],"phase":"phase_3","status":"active","brandName":"Ranibizumab injection and TTT - ICG based","genericName":"Ranibizumab injection and TTT - ICG based","companyName":"New England Retina Associates","companyId":"new-england-retina-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation. Used for Wet age-related macular degeneration (AMD), Retinal vein occlusion (RVO), Diabetic macular edema (DME).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}